It’s also a sign of efficacy of ICBT targeting PD-1/PD-L1 (Chen et al., 2016), as reported in B-cell lymphomas (Wang X. et al., 2016), breast cancer (Mittendorf et al., 2014), small-cell lung cancer (George et al., 2017) and pancreatic cancer (Wang et al., 2010). This evidence concerns the gene PDCD1 and breast cancer.